Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872243 | 1.00 | MEN1 (0.43) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL16409149 | 0.86 | MEN1 (0.43) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL12557612 | 0.85 | BTK (0.38) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL15424518 | 0.84 | MAPK1 (0.42) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL20629740 | 0.84 | MAPK1 (0.42) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL15424510 | 0.84 | MAPK1 (0.42) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL2630592 | 0.84 | KMT2A (0.42) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL18799610 | 0.83 | MEN1 (0.41) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL28564855 | 0.81 | KMT2A (0.40) | MEN1KMT2AMAPK1BTKNFKB1 | |
| SCHEMBL9666907 | 0.80 | KMT2A (0.39) | MEN1KMT2AMAPK1BTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450291-B2 | Method for producing fluorine-containing cyclopropane carboxylic acid compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20180186763-A1 | Method for Producing Fluorine-Containing Cyclopropane Carboxylic Acid Compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1748043-B1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7348344-B2 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1748043-A1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | MEN1 2716/4885KMT2A 3727/4885MAPK1 1363/4885 |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | MEN1 4801/4885KMT2A 4486/4885MAPK1 3159/4885 |
| US-20180186763-A1 | Method for Producing Fluorine-Containing Cyclopropane Carboxylic Acid Compound | PFAS, FDPS, FIBP | MEN1 2876/4885KMT2A 4361/4885MAPK1 2360/4885 |
| US-10450291-B2 | Method for producing fluorine-containing cyclopropane carboxylic acid compound | PFAS, FDPS, FIBP | MEN1 2876/4885KMT2A 4361/4885MAPK1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.